Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of the Efficacy and Safety of Step-wise Addition of Short Acting Insulin Analogue Insulin Aspart to Once Daily Insulin Detemir and Oral Anti-diabetic Treatment in Patients With Type 2 Diabetes

NCT00537303 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00537303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00537303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of the Efficacy and Safety of Step-wise Addition of Short Acting Insulin Analogue Insulin Aspart to Once Daily Insulin Detemir and Oral Anti-diabetic Treatment in Patients With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2007
Completion date
March 31, 2009
Enrollment
296 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2